Royalty Pharma price to book ratio RPRX

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 5.4×
6-year median: 3.8×
Against its 6-year history: 96th; percentile: 0 is its lowest day, 100 its highest
6-year range: 2.1× to 5.9×
Peer median: 5.5×

Royalty Pharma's price to book ratio is 5.4× as of Oct 23, 2026.

That is above its 6-year median of 3.8×, higher than on 96% of days in the last 6 years.

Over that time it ranged from 2.1× in Dec 2024 to 5.9× in Mar 2021.

The median for 10 healthcare stocks of a similar size is 5.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.4×	3.5×	5.4×
2025	3.5×	2.2×	3.6×
2024	2.2×	2.1×	2.8×
2023	2.7×	2.5×	4.1×
2022	3.9×	3.9×	4.6×
2021	4.2×	3.8×	5.9×
2020	4.4×	3.2×	4.4×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

Company	Price to book ratio
RPRXRoyalty Pharma	5.4×
RMDResMed	5.5×
BIIBBiogen	2.0×
CNCCentene	1.5×
ZTSZoetis	10.6×
MTDMettler-Toledo International	n/m
ILMNIllumina	14.3×
GEHCGE HealthCare Technologies	2.9×
ONCBeOne Medicines	8.3×
IDXXIDEXX Laboratories	27.4×
WATWaters	2.9×
Peer median	5.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.